JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting ...
JCR Pharmaceuticals announced the first patient dosed in Phase III trial of JR-142, a long-acting growth hormone therapy for pediatric growth hormone deficiency in Japan. The trial involves 54 pediatric patients and aims to compare JR-142's efficacy to JCR's existing product, Growject®, over a 52-week period.
Related News
JCR Pharmaceuticals Initiates Phase III Clinical Trial of JR-142 in Japan, a Long-Acting ...
JCR Pharmaceuticals announced the first patient dosed in Phase III trial of JR-142, a long-acting growth hormone therapy for pediatric growth hormone deficiency in Japan. The trial involves 54 pediatric patients and aims to compare JR-142's efficacy to JCR's existing product, Growject®, over a 52-week period.